Oto Jun, Suga Kenichi, Matsuura Sato, Kondo Shuji, Ohnishi Yoshiaki, Inui Daisuke, Imanaka Hideaki, Kagami Shoji, Nishimura Masaji
Department of Emergency and Critical Care Medicine, Tokushima University Hospital, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.
J Anesth. 2009;23(2):284-7. doi: 10.1007/s00540-008-0726-z. Epub 2009 May 15.
Focal segmental glomerulosclerosis (FSGS) often leads to refractory nephrotic syndrome (NS). A high level of low-density lipoprotein (LDL) is a risk factor for the progression of NS. An 8-year-old girl presented with severe proteinuria refractory to steroid therapy. She was diagnosed with non-IgA diffuse mesangial proliferative glomerulonephritis. Oral prednisolone, methylprednisolone (mPL) pulse therapy, and cyclosporine and cyclophosphamide therapy failed to achieve remission. Follow-up renal biopsy revealed FSGS. Her serum level of LDL was high, and LDL-apheresis (LDL-A) was performed five times, followed by mPL pulse therapy. Urinary protein decreased from 2-4 g x day(-) to 0.5-1.0 g x day(-). LDL-A may be beneficial in the treatment of multidrug-resistant FSGS.
局灶节段性肾小球硬化(FSGS)常导致难治性肾病综合征(NS)。低密度脂蛋白(LDL)水平升高是NS进展的危险因素。一名8岁女孩出现严重蛋白尿,对类固醇治疗无效。她被诊断为非IgA弥漫性系膜增生性肾小球肾炎。口服泼尼松龙、甲泼尼龙(mPL)冲击疗法、环孢素和环磷酰胺治疗均未达到缓解。随访肾活检显示为FSGS。她的血清LDL水平较高,进行了5次LDL吸附(LDL-A)治疗,随后进行mPL冲击疗法。尿蛋白从2 - 4 g×天⁻¹降至0.5 - 1.0 g×天⁻¹。LDL-A可能对多药耐药性FSGS的治疗有益。